Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Dummer, Reinhard; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; M. Kirkwood, John; Chiarion‐Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Lesimple, Thierry; Plummer, Ruth; Dasgupta, Kohinoor; Gasal, Eduard; Tan, Monique; V. Long, Georgina; Schadendorf, Dirk

doi:10.1056/nejmoa2005493

Public

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Published in New England Journal of Medicine • Sep 2, 2020

Authors:

Reinhard Dummer

Axel Hauschild

Mario Santinami

Abstract

Background In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability...

Subject

Dabrafenib

Trametinib

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!